A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

• Status: Recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ocular Therapeutix, Inc.
• Treatments: Bimatoprost; Travoprost

Criteria

Inclusion Criteria:

• Are 18 years of age or older at the time of screening

• Provide written informed consent and are able to comply with all study requirements

• Are willing to withhold glaucoma medications according to the study requirements, and in the opinion of the investigator can do so without significant risk

• Have a negative pregnancy test result for women of childbearing potential at Baseline

• Have a documented diagnosis of OHT, or OAG in the study eye

Exclusion Criteria:

• Have an uncontrolled systemic disease or a debilitating disease (e.g., cardiovascular, hypertension, uncontrolled diabetes)

• Are currently pregnant or breast-feeding or of childbearing potential without the use of adequate contraceptive methods during the length of the study

• Non-responsive to topical prostaglandins, prostamides or prostaglandin analogs